Gliosarcoma-Pipeline Review, H1 2015

Gliosarcoma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6801IDB
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Gliosarcoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Gliosarcoma-Pipeline Review, H1 2015', provides an overview of the Gliosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Gliosarcoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Gliosarcoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Gliosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Gliosarcoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Gliosarcoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Gliosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gliosarcoma Overview 6

Therapeutics Development 7

Pipeline Products for Gliosarcoma-Overview 7

Pipeline Products for Gliosarcoma-Comparative Analysis 8

Gliosarcoma-Therapeutics under Development by Companies 9

Gliosarcoma-Therapeutics under Investigation by Universities/Institutes 10

Gliosarcoma-Pipeline Products Glance 11

Clinical Stage Products 11

Gliosarcoma-Products under Development by Companies 12

Gliosarcoma-Products under Investigation by Universities/Institutes 13

Gliosarcoma-Companies Involved in Therapeutics Development 14

Amgen Inc. 14

Burzynski Research Institute, Inc. 15

Celgene Corporation 16

Merck & Co., Inc. 17

Millennium Pharmaceuticals, Inc. 18

NewLink Genetics Corporation 19

Sanofi 20

Gliosarcoma-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

alisertib-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Antineoplaston Therapy-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

CC-122-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

DNX-2401-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

indoximod-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

lonafarnib-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Oncolytic Virus to Target IL-12 for Oncology-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

plerixafor-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

rilotumumab-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

SGT-53-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Stem Cell Therapy for Glioma-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Gliosarcoma-Recent Pipeline Updates 52

Gliosarcoma-Dormant Projects 59

Gliosarcoma-Product Development Milestones 60

Featured News & Press Releases 60

Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

Number of Products under Development for Gliosarcoma, H1 2015 7

Number of Products under Development for Gliosarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Products under Investigation by Universities/Institutes, H1 2015 13

Gliosarcoma-Pipeline by Amgen Inc., H1 2015 14

Gliosarcoma-Pipeline by Burzynski Research Institute, Inc., H1 2015 15

Gliosarcoma-Pipeline by Celgene Corporation, H1 2015 16

Gliosarcoma-Pipeline by Merck & Co., Inc., H1 2015 17

Gliosarcoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 18

Gliosarcoma-Pipeline by NewLink Genetics Corporation, H1 2015 19

Gliosarcoma-Pipeline by Sanofi, H1 2015 20

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Stage and Target, H1 2015 23

Number of Products by Stage and Mechanism of Action, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Gliosarcoma Therapeutics-Recent Pipeline Updates, H1 2015 52

Gliosarcoma-Dormant Projects, H1 2015 59

List of Figures

Number of Products under Development for Gliosarcoma, H1 2015 7

Number of Products under Development for Gliosarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Top 10 Targets, H1 2015 22

Number of Products by Stage and Top 10 Targets, H1 2015 22

Number of Products by Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Amgen Inc.

Burzynski Research Institute, Inc.

Celgene Corporation

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

NewLink Genetics Corporation


Gliosarcoma Therapeutic Products under Development, Key Players in Gliosarcoma Therapeutics, Gliosarcoma Pipeline Overview, Gliosarcoma Pipeline, Gliosarcoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]